Every 10-Q that Alnylam Pharmaceuticals, Inc. (ALNY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALNY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALNY filings page.
Alnylam Pharmaceuticals reported higher revenue for the quarter ended June 30, 2026, with total revenues of 1,290,948, up from 773,689 a year earlier. Net product revenues rose to 1,172,109, led by AMVUTTRA at 1,011,762, while Rare disease products contributed 141,886. The company generated net income of 164,494 for the quarter and 370,485 for the first half, reversing prior-year losses.
Liquidity remains robust, with cash and cash equivalents of 1,708,318 and marketable debt securities of 1,599,829 as of June 30, 2026. Operating cash flow for the first half improved to 397,228. Stockholders’ equity increased to 1,354,118, while convertible debt totaled 1,010,981.
Alnylam continues to advance its RNAi-based pipeline and collaborations. The Roche zilebesiran agreement carried a total transaction price of 1,738,167, with 77,529 in related collaboration revenue recognized year‑to‑date. The company also recorded 51,356 in collaboration revenue from Regeneron and entered an AI‑driven discovery collaboration with Inceptive Nucleics, including a 15,000 preferred equity investment.
Alnylam Pharmaceuticals reported a strong turnaround for the quarter ended March 31, 2026. Total revenues rose to $1,167,175,000 from $594,189,000 a year earlier, driven mainly by net product revenues of $1,036,127,000, with AMVUTTRA contributing $889,931,000.
The company moved from a net loss of $18,251,000 to net income of $205,991,000, or $1.51 per diluted share, as higher sales outpaced increased research and development and selling, general and administrative expenses. Operating income rose to $268,636,000 from $18,077,000.
Alnylam ended the quarter with cash, cash equivalents and marketable debt securities totaling about $3.01 billion and total assets of $5,129,547,000. Stockholders’ equity increased to $1,075,380,000, while the company continued to carry convertible debt and significant liabilities related to the sale of future royalties and development funding.
Alnylam Pharmaceuticals reported strong Q3 2025 results, with total revenue of $1,249,026,000, up sharply year over year. Net product revenue reached $851,082,000, led by AMVUTTRA at $685,303,000, while collaboration revenue was $351,742,000, including a $300,000,000 Roche license milestone tied to the ZENITH Phase 3 initiation.
The company delivered income from operations of $367,982,000 and net income of $251,084,000, or $1.84 diluted EPS. Through nine months, operating cash flow was $360,525,000. The balance sheet showed cash and cash equivalents of $1,490,249,000 and marketable debt securities of $1,234,375,000, with convertible debt of $1,040,276,000. Accounts receivable increased to $964,768,000, reflecting higher sales and collaboration billings. Stockholders’ equity rose to $233,894,000, supported by profitability.
Within franchises, TTR therapies (AMVUTTRA and ONPATTRO) generated $724,378,000, and Rare (GIVLAARI and OXLUMO) delivered $126,704,000. At October 24, 2025, shares outstanding were 132,113,818.